Dr. Zacharias brings ten years of multifunctional and clinical leadership experience in the field of stem cell therapy research and development plus 14 years as a clinical small animal veterinarian. She has extensive experience in the scientific development and business operations of start-up biotech, led corporate efforts, R&D, clinical trials, and has considerable experience in regulatory compliance. In 2010, she co-founded a veterinary biotech company, Renovocyte, that made strides in stem cell therapy development in metabolic diseases in dogs and cats. In 2013, she was involved in the sale of the company to a global human medical company, Cook Group, Inc, where she remained an integral member of the executive leadership team as the Director of Veterinary Operations. At this time, she led the company into a partnership with a global animal health company where positive data was generated in continued stem cell studies in dogs and cats. In 2019, she was again involved in the acquisition of the veterinary stem cell R&D company by Gallant. Dr. Zacharias manages external professional relationships, interacts with medical doctors and veterinarians in a translational medicine aspect, and has experience conducting clinical trials. She was instrumental in the development of a new “off-the-shelf” cell therapy drug for the metabolic disease which she has been working toward FDA approval. Shelly holds a Bachelor of Science in Biochemistry from Cameron University as well as a Master of Arts in Secondary Science Education and a Doctor of Veterinary Medicine from the Oklahoma State College of Veterinary Medicine. She holds a certification in veterinary practice management (VPM) from Purdue University and has completed graduate-level studies in endocrinology prior to veterinary school. In 2020, she completed the board certification for a medical affairs specialist (ACMA).
View in org chart
View in org chart